Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

Jemperli sales hit $1B YTD, but AnaptysBio’s profits and revenue fell sharply year-over-year.

What the company is saying

AnaptysBio, led by CEO Daniel Faga, highlights Jemperli’s global net sales reaching $1.0 billion through September 30, 2026, and emphasizes continued commercial growth and recent U.S. FDA approval for a new indication. The company frames its core narrative around protecting and maximizing value from its financial collaborations, particularly as it approaches a court judgment in ongoing litigation with GSK and Tesaro and the FDA action date for Quimilza in December 2026. Management stresses the long-term royalty potential, projecting over $390 million in annualized Jemperli royalties as early as 2029 if GSK’s peak sales guidance of over $2.7 billion is met. The announcement details the impact of litigation costs and the reclassification of First Tracks Biotherapeutics as discontinued operations, explaining that the drop in collaboration revenue is due mainly to a $50 million milestone recognized in Q3 2025. The tone is measured, focusing on both realized achievements and significant forward-looking milestones, while acknowledging the financial impact of legal proceedings and operational transitions.

What the data suggests

Jemperli generated $365 million in global net sales in Q3 2026, up 20% year-over-year, and $1.0 billion for the first nine months of 2026, a 29% increase, though the prior-year sales figures are not disclosed for independent verification. AnaptysBio’s collaboration revenue dropped to $30.3 million in Q3 2026 from $76.3 million in Q3 2025, primarily because of a $50 million milestone booked in the prior year, partially offset by an 11% quarter-over-quarter increase in Jemperli royalties. Net income from continuing operations fell dramatically to $3.9 million ($0.13 per share) from $56.3 million ($2.02 per share) a year earlier. Cash, cash equivalents, and investments decreased by $11.1 million during the quarter, mainly due to $15.5 million in operating outflows, offset by $4.4 million from stock option exercises. General and administrative expenses surged to $11.6 million, up from $1.1 million, driven by $4.8 million in litigation costs and $2.2 million in recurring expenses. The company’s forward-looking claims, such as achieving over $390 million in annualized royalties by 2029 and full paydown of $270 million in non-recourse debt by H2 2027, are contingent on future sales growth and successful litigation or regulatory outcomes. The data is granular and transparent for current period results, but the most material upside remains speculative and several years away.

Analysis

The announcement provides a balanced mix of realised and forward-looking claims. Realised facts include Jemperli's $1.0 billion in net sales YTD, FDA approval for a new indication, and detailed financials showing positive net income, though sharply down year-over-year. However, several key claims are forward-looking, such as the expectation of >$390 million in annualized royalties by 2029, anticipated regulatory submissions in multiple regions, and the outcome of ongoing litigation. The most optimistic projections (peak royalties, debt paydown, regulatory wins) are long-dated and contingent on external factors (GSK's sales, regulatory approvals, litigation outcomes). The capital intensity flag is triggered by the scale of royalty monetization and the long wait for full paydown and peak royalty realization. While the tone is measured, the narrative leans on future milestones and large potential payouts, which are not yet secured. The gap between narrative and evidence is moderate: realised sales and royalties are strong, but the most material financial upside is several years away and not guaranteed.

Risk flags

• ●AnaptysBio’s financial performance deteriorated sharply year-over-year, with net income from continuing operations dropping from $56.3 million to $3.9 million and collaboration revenue falling from $76.3 million to $30.3 million. This exposes the company to ongoing profitability risk if milestone revenues do not recur and royalty growth is insufficient to offset lost one-time payments.
• ●A substantial portion of current expenses is driven by litigation, with $4.8 million in legal costs for the GSK and Tesaro lawsuit in Q3 2026 alone. The outcome of this litigation is uncertain, and an adverse judgment could materially impact future royalty streams and strategic options.
• ●The company’s most optimistic financial projections, such as achieving over $390 million in annualized royalties and full paydown of $270 million in non-recourse debt by H2 2027, are dependent on GSK’s ability to deliver sustained sales growth and on favorable regulatory and legal outcomes. Delays or setbacks in product approvals, sales ramp, or litigation could significantly defer or reduce these anticipated benefits.
• ●AnaptysBio’s cash and investment position declined by $11.1 million over the quarter, and while current liquidity remains adequate at $153.0 million, prolonged litigation or operational underperformance could pressure the balance sheet if not offset by future royalty inflows.

Bottom line

AnaptysBio’s Q3 2026 update shows strong realized Jemperli sales and a new FDA approval, but the company’s own revenue and profit have fallen sharply from last year, mainly due to the absence of one-off milestone payments and rising litigation costs. The near-term outlook hinges on two major events: the December 2026 FDA decision for Quimilza and a court ruling on the GSK/Tesaro litigation, both of which could materially affect future cash flows. While management projects substantial royalty growth and debt paydown by 2027–2029, these outcomes are not guaranteed and depend on external factors outside AnaptysBio’s control. The company’s disclosures are detailed and transparent, but the most significant financial upside remains several years away and subject to execution and legal risks. Investors should focus on the outcome of the litigation and regulatory milestones as the primary near-term catalysts. The key takeaway is that while current royalty streams are growing, the company’s profitability is under pressure, and the biggest potential rewards are still speculative and long-dated.

Announcement summary

(NASDAQ:ANAB) AnaptysBio, Inc. reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update. Jemperli achieved global net sales of $1.0 billion through September 30, 2026, with $365 million in global net sales for the three months ended September 30, 2026, representing 20% year-over-year growth. For the nine months ended September 30, 2026, Jemperli global net sales grew 29% year-over-year. Anaptys receives royalties equal to 12% of net sales between $1.0 billion and $1.5 billion in a given calendar year. Anaptys expects to achieve over $390 million in annualized Jemperli royalties as early as 2029 at GSK’s peak monotherapy sales guidance of over $2.7 billion. Anaptys estimates Sagard will have accrued approximately $330 million in royalties and sales milestones through September 30, 2026, and anticipates paydown of the remaining approximately $270 million non-recourse debt monetization in calendar H2 2027. GSK received FDA approval in October 2026 for Jemperli (dostarlimab) in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer, with first results from the AZUR-1 trial presented at ESMO Congress 2026 in Madrid, Spain, on October 25, 2026. Regulatory submission for Jemperli is expected in Japan in calendar H1 2027 and in Europe and China in calendar H2 2027, with a regulatory decision expected in Europe in calendar H2 2027. Data from the AZUR-2 pivotal Phase 3 trial and the JADE pivotal Phase 3 trial are expected in 2028, while the AZUR-4 Phase 2 trial has a primary completion date in Q4 2026. The FDA target action date (PDUFA) for Quimilza (imsidolimab) in generalized pustular psoriasis is December 12, 2026. The post-trial hearing in the GSK and Tesaro litigation was held before the Delaware Chancery Court on October 20, 2026, with Anaptys seeking reversion of Jemperli rights and anticipating a judgment in calendar Q4 2026 or Q1 2027. The separation of AnaptysBio and First Tracks Biotherapeutics was completed on April 20, 2026, and beginning in Q2 2026, AnaptysBio reclassified historical First Tracks Biotherapeutics, Inc. related assets, liabilities, and expenses as discontinued operations. Cash, cash equivalents, and investments totaled $153.0 million as of September 30, 2026, compared to $164.1 million as of June 30, 2026, for a decrease of $11.1 million, due primarily to $15.5 million used for operating activities offset by $4.4 million received from stock option exercises. Collaboration revenue was $30.3 million for the three months ended September 30, 2026, compared to $76.3 million for the same period in 2025, with the decrease primarily due to $50 million in milestone revenue recognized in Q3 2025, offset by Jemperli royalties increasing 11% quarter over quarter. General and administrative expenses from continuing operations were $11.6 million for the three months ended September 30, 2026, compared to $1.1 million for the same period in 2025, with $4.8 million in legal costs for the GSK and Tesaro litigation and $2.2 million in recurring expenses. G&A non-cash, stock-based compensation expense was $3.2 million for the three months ended September 30, 2026, compared to $0.5 million in 2025. Research and development expenses from continuing operations were a negative $1.3 million for the three months ended September 30, 2026, compared to a negative $2.0 million for the same period in 2025. Net income from continuing operations was $3.9 million for the three months ended September 30, 2026, or $0.13 per share, compared to $56.3 million, or $2.02 per share, for the same period in 2025. Total assets as of September 30, 2026, were $307,043,000, and total liabilities and stockholders’ equity matched this amount. The weighted-average number of shares outstanding was 29,847 basic and 35,072 diluted for the three months ended September 30, 2026.

Disagree with this article?